Fetuin-A: The Rising Star in Diabetic Retinopathy Detection

Summary: A comprehensive systematic review and meta-analysis published in the Journal of Diabetes & Metabolic Disorders reveals the potential of fetuin-A as a biomarker for diabetic retinopathy (DR). Key findings include:

1. Fetuin-A levels were significantly higher in DR patients compared to both non-DR diabetic patients and healthy controls.
2. Patients with proliferative DR showed higher fetuin-A levels than those with non-proliferative DR.
3. No significant difference in fetuin-A levels was found between diabetic patients without DR and healthy controls.
4. The study analyzed data from 7 studies, including 1104 cases with a mean age of 57.24 ± 9.62 years.
5. These findings suggest fetuin-A could potentially be used as a clinical biomarker for DR, pending confirmation from larger studies.

This research highlights the promising role of fetuin-A in DR detection and progression monitoring, potentially improving early diagnosis and management of this vision-threatening complication.

Reference: Behnoush, A.H., Samavarchitehrani, A., Shirazi Ghaleno, A.M., & Klisic, A. (2025). Fetuin-A levels in diabetic retinopathy: a systematic review and meta-analysis. Journal of Diabetes & Metabolic Disorders, 24, 31. https://doi.org/10.1007/s40200-024-01533-0

Our weekly OniX OnPoint Newsletter and daily LinkedIn Update works in tandem, focusing this week on diabetic retinopathy research and opportunities. Gain insights to identify early-stage assets, connect with key opinion leaders, explore strategic partnerships, and discover licensing opportunities in this rapidly evolving field.

Hashtags:#DiabeticRetinopathy #FetuinA #BiomarkerResearch #DiabetesComplications #OphthalmologyInnovation #MetabolicDisorders